Loading...
Results were just released from two randomized, double-blinded trials of oral pre-exposure prophylaxis (PrEP) in heterosexual men and women.
In the CDC TDF2 study, 1200 HIV-uninfected men and women in Botswana were randomized to take oral tenofovir/FTC or placebo daily. The tenofovir/FTC group was found to have a 63% reduction in the risk for HIV acquisition. The reduction was even greater (78%) among individuals believed to be actually taking the study drugs.
In the Partners PrEP Study, the uninfected partners in nearly 4800 HIV-serodiscordant couples in Kenya and Uganda were randomized to take oral tenofovir/FTC, oral tenofovir alone, or oral placebo daily. Relative to placebo, tenofovir/FTC was associated with a 73% reduction in risk for HIV acquisition, and tenofovir alone was associated with a 62% reduction in risk. The protective effects were similar for both men and women.
In his blog HIV and ID Observations, Paul Sax, MD, tallies up the results of the various PrEP studies and offers his take on where we should go from here.